Identity
- Security key
- 20942
- Ticker
- RGEN
- Type
- CS — Common Stock
- Exchange
- Nasdaq(XNAS)
- Venue group
- NASDAQ
- Operating MIC
- XNAS
- Market
- stocks
- Locale
- us
- Currency
- USD
- Listed
- 1986-04-29
- Round lot
- 100
- Active
- Yes
- Last seen in a load
- 2026-08-14 20:49
- Vendor updated
- 2026-08-13 06:09
- Ticker root / suffix
- RGEN
Detail
Enriched 2026-08-14 20:47
- Market cap
- $9,351,382,399.7
- Shares outstanding (class)
- 56,435,621
- Shares outstanding (weighted)
- 56,435,621
- SIC
- 2836 BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
- Employees
- 2,000
- Location
- WALTHAM, MA
- Homepage
- https://www.repligen.com
- Description
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia-Pacific contribute about 44%, 37%, and 19% of revenue, respectively.